Exelixis Stock News

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the

Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with

These great businesses have been money machines for investors over the long run.

State of Tennessee Treasury Department grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 72.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Se

These companies have products, products, and more products to keep revenue flowing.

Exelixis, Inc. (NASDAQ:EXEL) BofA Securities Napa Biopharma Conference Call June 24, 2020 3:30 P.M. ET Company Participants Mike Morrissey - President and Chief

Exelixis, Inc. (NASDAQ:EXEL) BMO Capital Markets Prescription for Success Healthcare Conference June 23, 2020, 16:00 ET Company Participants Michael Morrissey -

Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

NEW YORK--(BUSINESS WIRE)--Innovatus Capital Partners, LLC ("Innovatus" or the "Firm"), an independent adviser and portfolio management firm with approximately $1.6 billion in asse

Victory Capital Management Inc. lowered its stake in Exelixis, Inc. (NASDAQ:EXEL) by 36.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission.

Innovatus Capital Partners, LLC (

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in a fireside chat as part of the virtual BofA S

Massachusetts Financial Services Co. MA lowered its position in Exelixis, Inc. (NASDAQ:EXEL) by 68.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC.